Photo taken from: The European Society for Medical Oncology (ESMO)/LinkedIn
Mar 1, 2024, 16:32
Yardena Samuels discusses how ongoing research is revisiting the classic neoantigen approach – The European Society for Medical Oncology (ESMO)
The European Society for Medical Oncology (ESMO) posted on LinkedIn:
“ESMOTAT24: Novel antigens for cancer immunotherapy – a way to enhance effectiveness?
Yardena Samuels discusses how ongoing research is revisiting the classic neoantigen approach that may better interpret the complexity of the immune system.
To learn more about this topic, read the ESMO Daily Reporter article.”
Source: The European Society for Medical Oncology (ESMO)/LinkedIn